NEW ORLEANS — People fighting chronic myeloid leukemia got a double dose of good news at the meeting of the American Society of Hematology.
The drug nilotinib, marketed as Tasigna, proved better than the reigning frontline drug used against CML, a new study finds. “Based on these results, we strongly believe that nilotinib may become the new standard of care in newly diagnosed CML patients,“ says Giuseppe Saglio, a hematologist at the University of Turin in Italy.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.